IMCR

$30.74+0.17 (+0.56%)

Market OpenAs of Mar 17, 5:07 PM UTC

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$30.74
Potential Upside
5%
Whystock Fair Value$32.28
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internatio...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-9.58%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.91

Recent News

The Fly
Mar 16, 2026

Qualcomm, Adobe downgraded: Wall Street's top analyst calls

Qualcomm, Adobe downgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 1, 2026

Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress?

If you are trying to figure out whether Immunocore Holdings is attractively priced or already reflecting its potential, you are in the right place for a clear valuation breakdown. The share price closed at US$32.30 recently, with a 10.0% return over the past year but a 39.5% decline over three years and a 4.4% decline year to date, which may point to shifting views on both opportunity and risk. Recent news flow around Immunocore has focused on its pipeline progress and partnerships, which...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 25, 2026

Immunocore Q4 Earnings Call Highlights

Immunocore (NASDAQ:IMCR) executives highlighted continued commercial momentum for KIMMTRAK and progress across a diversified pipeline during the company’s fourth-quarter and full-year 2025 earnings call. Management emphasized that 2025 results reflected “consistent execution” and pointed investors t

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 25, 2026

Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ...

Immunocore Holdings PLC (IMCR) reports a 29% revenue increase driven by KimTrack's success, while advancing its oncology and infectious disease programs.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 25, 2026

JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations

Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.